About Crucell
Crucell is a Healthcare company based in Leiden (Netherlands) founded in 1993, and was acquired by Johnson & Johnson in September 2010. Crucell researches and develops products and markets vaccines, proteins and antibodies for the treatment of infectious diseases. Crucell has raised $443 million across 2 funding rounds from investors including Johnson & Johnson and European Union. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent andor treat infectious diseases. Crucells core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
- Headquarters Leiden, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website crucell.com
- Social LinkedIn
- Acquired by Johnson & Johnson (Sep 2010)
- Total Equity Funding$443M (USD)
in 2 rounds
- Latest Funding Round$92.14K (USD), Grant
Jan 2016
- InvestorsJohnson & Johnson
& 1 more
- Acquired byJohnson & Johnson
(Sep 2010)
Funding Insights of Crucell
Crucell has successfully raised a total of $443M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $92.14 thousand completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $443M
- Total Rounds 2
- Last Round Grant — $92,142
- First Round $443M
(Sep 2009)
- Investors Count 2
All 2 funding rounds of Crucell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $92,142 | Grant | – | – | |
| Sep 2009 | $443M | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in Crucell
Crucell has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Johnson & Johnson and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Healthcare solutions are provided by Johnson & Johnson globally. | 1886 | jnj.com | New Brunswick, United States |
Investor details for Crucell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Crucell
1 people are tracked at Crucell (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ronald Brus | CEO | Leadership |
Complete people profiles for Crucell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Crucell
4 dated milestones of Crucell across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Crucell is founded.
- Funding First funding round of $443.0M.
- Exit Acquired by Johnson & Johnson.
- Funding Latest funding round, Grant, of $92K.
Web traffic of Crucell
Websites that share an audience with Crucell (crucell.com).
Websites whose visitors overlap most with Crucell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sanofipasteur.com | sanofipasteur.com | 100% | – | ||
| novartis.com | 99% | 948.8K | #58,822 | View details | |
| medimmune.com | 97% | View details | |||
| argostherapeutics.com | 96% | View details | |||
dnavaccine.com | dnavaccine.com | 95% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Crucell
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crucell
Complete news archive for Crucell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crucell
Crucell was founded in 1993 and raised its 1st funding round 16 years after it was founded.
Crucell is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Crucell is a funded company, having raised a total of $443M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $443M, raised on Sep 2009.
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent andor treat infectious diseases. Crucells core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
Crucell has 2 investors. Key investors include Johnson & Johnson, and European Union.
Yes. Crucell was acquired by Johnson & Johnson in September 2010.